Clinical study on acupuncture acupoints around the eyes in treating myopia in children and adolescents

注册号:

Registration number:

ITMCTR2000004045

最近更新日期:

Date of Last Refreshed on:

2020-09-03

注册时间:

Date of Registration:

2020-09-03

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

针刺眼周腧穴治疗儿童青少年近视的临床研究

Public title:

Clinical study on acupuncture acupoints around the eyes in treating myopia in children and adolescents

注册题目简写:

English Acronym:

研究课题的正式科学名称:

针刺眼周腧穴治疗儿童青少年近视的临床研究

Scientific title:

Clinical study on acupuncture acupoints around the eyes in treating myopia in children and adolescents

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

CJJ2019030

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2000037874 ; ChiMCTR2000004045

申请注册联系人:

黄群

研究负责人:

黄群

Applicant:

Huang Qun

Study leader:

Huang Qun

申请注册联系人电话:

Applicant telephone:

+86 13540713675

研究负责人电话:

Study leader's telephone:

+86 13540713675

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1015451803@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1015451803@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

四川省成都市十二桥路39号成都中医药大学附属医院

研究负责人通讯地址:

四川省成都市十二桥路39号成都中医药大学附属医院

Applicant address:

39 Shi'erqiao Road, Jinniu District, Chengdu, Sichuan, China

Study leader's address:

39 Shi'erqiao Road, Jinniu District, Chengdu, Sichuan, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

成都中医药大学附属医院

Applicant's institution:

Hospital of Chengdu University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

ChiECRCT20200196

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

中国注册临床试验伦理委员会

Name of the ethic committee:

Chinese Ethics Committee of Registering Clinical Trials

伦理委员会批准日期:

Date of approved by ethic committee:

2020/7/30 0:00:00

伦理委员会联系人:

米娜

Contact Name of the ethic committee:

Mina

伦理委员会联系地址:

中国香港特别行政区九龙塘浸会大学道中国临床试验注册中心香港中心

Contact Address of the ethic committee:

Chinese Clinical Trial Registry Hong Kong Center, Hong Kong Baptist University Road, Hong Kong SAR, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

成都中医药大学附属医院

Primary sponsor:

Hospital of Chengdu University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

四川省成都市十二桥路39号

Primary sponsor's address:

39 Shi'erqiao Road, Jinniu District, Chengdu, Sichuan, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

成都中医药大学附属医院

具体地址:

十二桥路39号

Institution
hospital:

Hospital of Chengdu University of Traditional Chinese Medicine

Address:

39 Shi'erqiao Road, Jinniv District

经费或物资来源:

第三届四川省十大名中医工作室建设资助

Source(s) of funding:

The third Sichuan Ten famous Chinese medicine studio construction funding

研究疾病:

近视

研究疾病代码:

Target disease:

Myopia

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

通过随机临床对照试验,从有科学依据方法的立足点出发评估针刺治疗眼周腧穴治疗儿童青少年近视的疗效,为中医治疗治疗儿童青少年近视提供循证医学证据,为儿童青少年近视的防控提供有效、安全的方法。

Objectives of Study:

Through the randomized controlled clinical trial, the curative effect of acupuncture on children and adolescents with peri-ocular acupoint on myopia was evaluated based on scientific methods, which provided evidence-based medical evidence for TCM treatment of children and adolescents with myopia, and provided effective and safe methods for the prevention and control of children and adolescents with myopia.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

①符合儿童青少年近视诊断标准; ②年龄7-16岁; ③签署知情同意书,获取知情同意书的过程符合临床试验管理规范的要求。

Inclusion criteria

1. Patients who meet the diagnostic criteria of myopia in children and adolescents; 2. Patients aged 7-16 years; 3. The patients who signed the informed consent form, the process of obtaining the informed consent conforms to the requirements of clinical trial management norms.

排除标准:

①有斜视或弱视的患者; ②近视与视网膜营养不良或发育障碍有关; ③合并有心脑血管、肝肾及造血系统等严重原发疾病者,精神病患者; ④2周内使用其他相关药物或者治疗近视的患者; ⑤屈光度<-0.5D,或与病理性近视相关的眼底改变和(或)显著的是功能损害相结合; ⑥依从性较差,在14周内无法获得屈光数据,正参加其他临床试验者。

Exclusion criteria:

1. Strabismus or amblyopia; 2. Myopia is associated with retinal dystrophy or developmental disorders; 3. Patients with severe primary diseases such as cardio cerebrovascular disease, liver and kidney disease, hematopoiesis system, and psychotic patients; 4. Patients who use other related drugs or treat myopia within 2 weeks; 5. Patients with diopter less than - 0.5d, or fundus changes associated with pathological myopia and / or significant functional impairment; 6. Patients with poor compliance were unable to obtain refractive data within 14 weeks and were participating in other clinical trials.

研究实施时间:

Study execute time:

From 2020-08-17

To      2023-08-01

征募观察对象时间:

Recruiting time:

From 2020-08-17

To      2021-08-01

干预措施:

Interventions:

组别:

揿针假穴组

样本量:

100

Group:

Press acupuncture false point group

Sample size:

干预措施:

揿针假穴

干预措施代码:

Intervention:

Press acupuncture false point

Intervention code:

组别:

揿针组

样本量:

100

Group:

Press needle group

Sample size:

干预措施:

揿针治疗

干预措施代码:

Intervention:

Press needle treatment

Intervention code:

组别:

针刺组

样本量:

100

Group:

Acupuncture group

Sample size:

干预措施:

针刺治疗

干预措施代码:

Intervention:

Acupuncture treatment

Intervention code:

组别:

针刺假穴组

样本量:

100

Group:

Acupuncture false point group

Sample size:

干预措施:

针刺假穴

干预措施代码:

Intervention:

Acupuncture false point

Intervention code:

样本总量 Total sample size : 400

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

成都中医药大学附属医院

单位级别:

三甲

Institution/hospital:

Hospital of Chengdu University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

屈光度情况

指标类型:

主要指标

Outcome:

Diopter situation

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

角膜曲率

指标类型:

次要指标

Outcome:

Corneal curvature

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

裸眼视力

指标类型:

次要指标

Outcome:

Naked eyesight

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

眼轴长度

指标类型:

次要指标

Outcome:

Eye axis length

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

最佳矫正视力

指标类型:

次要指标

Outcome:

Best corrected vision

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医证候评分

指标类型:

次要指标

Outcome:

TCM syndrome score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Bood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

粪便

组织:

Sample Name:

stool

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 7
Min age years
最大 16
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用中央随机系统实现分层区组随机的分组与随机隐藏。按照分中心进行分层,区组段长为4,按1:1:1:1比例随机分为针刺组、揿针组、针刺假穴组和揿针假穴组。由四川省中医药循证医学中心的一名统计师使用SAS软件三轮循环随机语句生成随机序列,列出流水号为 001-400所对应的随机编码表,产生400例受试者的治疗分配。此过程由网络版中央随机系统实现,研究者在中央随机系统上录入预期受试者的筛选信息,获得受试者编号,符合受试者标准且签署知情同意书后随机分组,产生随机号,受试者与研究者无法预见受试者的分组信息,随机号由四川省中医药循证医学中心系统管理。直到研究结束时,受试者、临床医师、结果测量者均不知道受试对象分组的情况。

Randomization Procedure (please state who generates the random number sequence and by what method):

A central random system is used to achieve random grouping and random hiding of stratified blocks. Stratified according to the sub-center, the block length is 4, and they are randomly divided into acupuncture group, press needle group, acupuncture fake acupoint group and press acupuncture fake acupoint group.

盲法:

对受试者设盲

Blinding:

Blind method for subjects

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

临床试验公共管理平台ResMan

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Clinical Trial Management Public Platform ResMan, http://www.medresman.org.cn

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

(1)病例报告表填写与移交:病例报告表由研究者填写,每位入选病例必须完成病例报告表。完成病例报告表由临床监察员审查后,第一联移交数据管理员,进行数据录入与管理工作。第一联移交后,病例报告表的内容不再做修改。 (2)数据录入与修改:数据录入与管理将聘请医学统计专家指定专门数据管理员负责。数据管理员采用EpiData软件编制数据录入程序,进行数据录入与管理。为保证数据准确性,应由两位数据管理员独立进行双份录入并校对。对病例报告表中存在的疑问,数据管理员将根据产生疑问解答表(DRQ)中内容,并通过临床监察员向研究者发出询问,研究者应尽快解答并返回,数据管理员根据研究者的回答进行数据修改、确认与录入。 (3)数据锁定:在审核并确认建立的数据库正确后,由项目主持单位、主要研究者、统计分析人员对数据进行锁定。锁定后的数据或文件不再做改动。数据锁定之后发现的问题,经确认后在统计分析程序中进行修正。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

1. Filling and handing over the case report form: The case report form is filled out by the researcher, and each selected case must complete the case report form. After the case report form is reviewed by the clinical supervisor, the first page is transferred to the data manager for data entry and management. After the transfer of the first page, the contents of the case report form will no longer be modified. 2. Data entry and modification: data entry and management will hire medical statistic experts to designate special data administrators. Data administrators use EpiData software to compile data entry procedures for data entry and management. In order to ensure the accuracy of the data, two data administrators should independently perform double entry and proofreading. For the questions in the case report form, the data administrator will issue questions to the investigator through the clinical monitor according to the content in the Question Answer Form (DRQ). The investigator should answer and return as soon as possible. Respond to data modification, confirmation and entry. 3. Data lock: After reviewing and confirming that the established database is correct, the project leader, main researchers, and statistical analysts lock the data. The locked data or files will no longer be changed. The problems found after the data is locked, after confirmation, will be corrected in the statistical analysis program.

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above